Olr348 inhibitors represent a specialized category of chemical compounds known for their ability to interact with the Olfactory receptor 348 (Olr348), a specific member of the olfactory receptor family. Olfactory receptors are a broad class of G-protein-coupled receptors (GPCRs) primarily recognized for their role in the detection of odorant molecules, facilitating the sense of smell. Olr348, like other olfactory receptors, is a seven-transmembrane domain protein that transduces signals via G-proteins, leading to intracellular responses. The inhibitors of Olr348 are characterized by their capacity to bind to this receptor, potentially altering its conformational state, and subsequently modulating its signaling pathways. These inhibitors are often designed with structural motifs that mimic or compete with natural ligands of the receptor, thus offering a tool to study the receptor's function and behavior in various biological contexts.
The study of Olr348 inhibitors is significant for advancing the understanding of olfactory signal transduction mechanisms. The inhibition of Olr348 can reveal insights into the receptor's ligand specificity, binding affinities, and downstream signaling cascades. Researchers often explore the structural activity relationships (SAR) of these inhibitors to delineate the molecular interactions at the receptor's active site. This information is invaluable for constructing detailed models of Olr348's functional architecture. Additionally, the exploration of Olr348 inhibitors contributes to broader research into GPCR function, offering perspectives on how specific receptor subtypes are regulated and how they contribute to sensory perception and cellular communication. These inhibitors, therefore, serve as critical molecular tools in the field of receptor biology, enabling the dissection of complex signaling networks and the characterization of olfactory receptor dynamics at a molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor, may halt signal transduction and cell proliferation in specific cancer types. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor, may disrupt cell growth and proliferation in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor, potentially affects cell signaling in various cancers. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, could induce apoptosis in cancer cells. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits MET, VEGFR, and RET, potentially disrupts tumor growth and angiogenesis. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Multi-kinase inhibitor, may affect tumor angiogenesis and growth. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
BTK inhibitor, potentially disrupts B-cell receptor signaling in certain cancers. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, could impede cell proliferation in EGFR-mutated lung cancers. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, may disrupt cell signaling and angiogenesis in various cancers. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, could impair cell proliferation and survival in specific cancer types. | ||||||